Receptor Binding Radiotracers 1982

This series of books on Radiotracers in Biology and Medicine is on the one hand an unbelievably expansive enterprise and on the other hand, a most noble one as well. Tools to probe biology have developed at an accelerating rate. Hevesy pioneered the application of radioisotopes to the study of chemical processes, and since that time radioisotopic methodology has probably contributed as much as any other methodology to the analysis of the fine structure of biologic systems. Radioisotopic methodologies represent powerful tools for the determination of virtually any process of biologic interest. It should not be surprising, therefore, that any effort to encompass all aspects of radiotracer methodology is both desirable in the extreme and doomed to at least some degree of inherent failure. The current series is assuredly a success relative to the breadth of topics which range from in depth treatise of fundamental science or abstract concepts to detailed and specific applications, such as those medicine or even to the extreme of the methodology for sacrifice of anaimals as part of a radiotracer distribution study.

First Published in 1982, this book explores the role of receptor-binding radiotracers. Carefully compiled and filled with a vast repertoire of notes, diagrams, and references this book serves as a useful reference for Students of radiology, and other practitioners in their respective fields.

This volume is the result of the concerted effeort of a number os scientists to summarize in a succinct way the current understanding of the mechanisms of these localizations. The editors of the book gratefully acknowledge this combined effort.

Cardiovascular Molecular Imaging is based on a groundbreaking NIH symposium sponsored by the American Society of Nuclear Cardiology. The first all-inclusive guide to the targeted molecular imaging of the cardiovascular system, it includes color illustrations throughout and is packaged with a user-friendly CD-ROM with supplemental material.This refe

The editors have asked me to write this foreword probably for two reasons: First, I have spent 35 years trying to develop radiolabeled compounds that would help diagnose and treat disease. I, and the people from my laboratory, have been much involved with developing Nan'I for the diagnosis and treatment of hyperthyroidism and well-differentiated thyroid cancer. Second, I was a participant throughout the entire symposium upon which this book is based. Our latest '311-labeled compound, [l3lll metaiodobenzylguanidine, took us 13 years to develop. It has succeeded in diagnosing and treating adrenergic tumors '31 under circumstances where Na 1 would have failed for the diagnosis and treatment of thyroid cancer. I therefore hope that more scientists will be attracted to this field. This book is written by intelligent, experienced investigators who are knowl edgeable. It is a must for anyone new in the field. For the experienced, I would like to remind you that I attended the entire symposium; the breadth and timeliness of the update has helped us to redirect some of our current efforts into more scientifically productive channels. William H. Beierwaltes, M.D.